SHIFT Newsroom · GLOBAL
UBT251: early human study results published
The cited paper reports results from randomised, placebo-controlled phase 1a and 1b studies of UBT251, rather than announcing that those studies are only beginning.
The cited paper reports results from randomised, placebo-controlled phase 1a and 1b studies of UBT251, rather than announcing that those studies are only beginning. It examines safety, tolerability, drug exposure and early metabolic outcomes; repeated treatment lasted twelve weeks in the phase 1b study. Early results cannot establish long-term safety, comparative effectiveness or UK access.
SHIFT’s take
Read the study design and limits alongside the finding. This article does not determine individual treatment suitability.